The 340B Drug Pricing Program “has enabled hospitals and health systems to support and expand access and services consistent with their mission and the program’s original and ongoing charge,” the AHA and Association of American Medical Colleges today told leaders of the House Energy and Commerce Committee and its Subcommittee on Oversight and Investigations. In the letter, AHA and AAMC provided examples of how hospitals and health systems have used 340B savings to expand access and services. These include supporting neonatal intensive care units and training for physicians to care for vulnerable newborns; providing low-income patients with free outpatient drugs; and pharmacist counseling services for medication therapy disease management, including telephone consultations for outpatients with conditions such as diabetes, hypertension and asthma. The letter also notes that the 340B program is not federally funded, and 340B sales are less than 3% of the total U.S. drug market. The Oversight and Investigations Subcommittee will hold a hearing on the 340B program Oct. 11.

Headline
UnitedHealth Group announced plans to expand its Rural Payment Acceleration Pilot to reduce Medicare Advantage payment processing times for…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The AHA and dozens of other organizations April 14 sent a letter of support to Reps. Suzan DelBene, D-Wash., and Mike Kelly, R-Pa., for their introduction…
Headline
The Medicare Payment Advisory Commission met April 9 and 10 to discuss several topics, including the relationship between Medicare Advantage enrollment and…
Headline
The Centers for Medicare & Medicaid Services issued an updated registration link for its webinar April 16 at 3 p.m. ET on Medicare Clinical…